Summary
The orally active angiotensin-converting enzyme inhibitor captopril was administered for up to 11 weeks to three patients with progressive systemic sclerosis presenting with hypertension and plasma creatinine levels of 3.1, 7.2 and 10.4 mg/100 ml. Only one patient had malignant phase hypertension. In this patient a diuretic had to be added to captopril in order to keep blood pressure under control. Despite sustained blood pressure control during captopril administration, renal function deteriorated and hemodialysis treatment had to be started in all patients. Up to that time no substantial improvement in skin lesions was observed. During the period of dialysis, blood pressure was normal in all patients even though administration of captopril was discontinued. All three patients died of respiratory failure while on chronic hemodialysis for 3 to 4 weeks. These observations confirm that angiotensin-converting enzyme inhibition may be helpful in controlling blood pressure of patients with scleroderma. However, in contrast to some earlier reports, they also indicate that converting enzyme inhibition does not always prevent the multivisceral vascular lesions of scleroderma.
Similar content being viewed by others
References
Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, Le Roy EC (1974) The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine 53:1–46
Medsger TA, Masi AT, Rodman GP, Benedek TG, Robinson H (1971) Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 75:369–376
Richardson JA (1973) Hemodialysis and kidney transplantation for renal failure from scleroderma. Arthritis and Rheumatism 16:265–271
Shapiro CB, Lerner NE, Ackad AS, Abramson RG, Stein RM (1977) Malignant hypertension and uremia in scleroderma: efficacy of nephrectomy and hemodialysis. Clin Nephrol 8:321–323
LeRoy EC, Fleischmann RM (1978) The management of renal scleroderma. Am J Med 64:974–978
Lopez-Ovejero JA, Saal SD, D'Angelo WA, Cheigh JS, Stenzel KH, Laragh JH (1979) Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 25:1417–1419
Zawda ET Jr, Clements PJ, Furst DA, Bloomer HA, Paulus HE, Maxwell MH (1981) Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron 27:74–78
Mitnick PD, Feig PU (1978) Control of hypertension and reversal of renal failure in scleroderma. N Engl J Med 16:871–872
Wasner C, Cooke CR, Fries JF (1978) Successful medical treatment of scleroderma renal crisis. N Engl J Med 16:873–875
Stone RA, Tisher CC, Hawkins HK, Robinson RR (1974) Juxtaglomerular hyperplasia and hyperreninemia in progressive systemic sclerosis complicated by acute renal failure. Am J Med 56:119–123
Gavras H, Gavras I, Cannon PJ, Brunner HR, Laragh JH (1977) Is elevated plasma renin activity of prognostic importance in progressive systemic sclerosis? Arch Intern Med 137:1554–1558
Whitman III HH, Case DB, Laragh JH, Christian CL, Botstein G, Maricq H, LeRoy EC (1982) Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Arthritis and Rheumatism 25:241–248
Author information
Authors and Affiliations
Additional information
This study was supported in part by grant Nos. 3.914.080 and 3.824.081 of the Swiss National Science Foundation
Rights and permissions
About this article
Cite this article
Waeber, B., Schaller, M.D., Wauters, J.P. et al. Deterioration of renal function in hypertensive patients with scleroderma despite blood pressure normalization with captopril. Klin Wochenschr 62, 728–730 (1984). https://doi.org/10.1007/BF01725706
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01725706